Visgeneer
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, Zeaxanthin, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cr… Read more
Visgeneer (4197) - Net Assets
Latest net assets as of June 2025: NT$196.13 Million TWD
Based on the latest financial reports, Visgeneer (4197) has net assets worth NT$196.13 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$343.71 Million) and total liabilities (NT$147.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$196.13 Million |
| % of Total Assets | 57.06% |
| Annual Growth Rate | -0.17% |
| 5-Year Change | -11.08% |
| 10-Year Change | -38.6% |
| Growth Volatility | 10.82 |
Visgeneer - Net Assets Trend (2011–2024)
This chart illustrates how Visgeneer's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Visgeneer (2011–2024)
The table below shows the annual net assets of Visgeneer from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$193.84 Million | -8.38% |
| 2023-12-31 | NT$211.57 Million | -8.47% |
| 2022-12-31 | NT$231.16 Million | +5.64% |
| 2021-12-31 | NT$218.81 Million | +0.38% |
| 2020-12-31 | NT$218.00 Million | +0.28% |
| 2019-12-31 | NT$217.39 Million | -12.75% |
| 2018-12-31 | NT$249.15 Million | -11.35% |
| 2017-12-31 | NT$281.04 Million | -9.84% |
| 2016-12-31 | NT$311.69 Million | -1.27% |
| 2015-12-31 | NT$315.69 Million | +2.08% |
| 2014-12-31 | NT$309.25 Million | +8.28% |
| 2013-12-31 | NT$285.60 Million | +14.14% |
| 2012-12-31 | NT$250.23 Million | +26.23% |
| 2011-12-31 | NT$198.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Visgeneer's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11806000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$311.90 Million | 160.91% |
| Total Equity | NT$193.84 Million | 100.00% |
Visgeneer Competitors by Market Cap
The table below lists competitors of Visgeneer ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PUDO Inc
OTCQB:PDPTF
|
$5.70 Million |
|
CADENCE MINERALS LS -01
F:2REA
|
$5.70 Million |
|
Innovative Eyewear Inc.
NASDAQ:LUCY
|
$5.71 Million |
|
Bettermoo(d) Food Corporation
OTCQB:MOOOF
|
$5.71 Million |
|
Move Logistics Group Ltd
AU:MOV
|
$5.70 Million |
|
Boron One Holdings Inc.
V:BONE
|
$5.70 Million |
|
Noble Romans Inc
OTCQB:NROM
|
$5.70 Million |
|
U10 SA
PA:ALU10
|
$5.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Visgeneer's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 211,571,000 to 193,842,000, a change of -17,729,000 (-8.4%).
- Net loss of 17,729,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-17.73 Million | -9.15% |
| Total Change | NT$- | -8.38% |
Book Value vs Market Value Analysis
This analysis compares Visgeneer's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.01x to 1.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$9.31 | NT$9.42 | x |
| 2018-12-31 | NT$8.26 | NT$9.42 | x |
| 2019-12-31 | NT$7.20 | NT$9.42 | x |
| 2020-12-31 | NT$7.22 | NT$9.42 | x |
| 2021-12-31 | NT$7.25 | NT$9.42 | x |
| 2022-12-31 | NT$7.66 | NT$9.42 | x |
| 2023-12-31 | NT$7.01 | NT$9.42 | x |
| 2024-12-31 | NT$6.42 | NT$9.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Visgeneer utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.32%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.71x
- Recent ROE (-9.15%) is below the historical average (-2.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 11.28% | 16.10% | 0.60x | 1.16x | NT$3.66 Million |
| 2014 | 6.54% | 9.97% | 0.53x | 1.23x | NT$-10.71 Million |
| 2015 | 7.06% | 10.77% | 0.38x | 1.71x | NT$-9.28 Million |
| 2016 | 0.12% | 0.23% | 0.31x | 1.67x | NT$-30.79 Million |
| 2017 | -10.91% | -19.45% | 0.29x | 1.95x | NT$-58.76 Million |
| 2018 | -12.80% | -22.37% | 0.32x | 1.81x | NT$-56.80 Million |
| 2019 | -14.61% | -20.89% | 0.32x | 2.21x | NT$-53.49 Million |
| 2020 | 0.28% | 0.34% | 0.38x | 2.12x | NT$-21.20 Million |
| 2021 | 0.37% | 0.50% | 0.39x | 1.95x | NT$-21.06 Million |
| 2022 | 5.34% | 7.82% | 0.32x | 2.11x | NT$-10.77 Million |
| 2023 | -9.26% | -13.24% | 0.37x | 1.88x | NT$-40.75 Million |
| 2024 | -9.15% | -15.32% | 0.35x | 1.71x | NT$-37.11 Million |
Industry Comparison
This section compares Visgeneer's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Visgeneer (4197) | NT$196.13 Million | 11.28% | 0.75x | $5.70 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |